Foundation Medicine entered into a contract with the Department of Veterans Affairs' national precision oncology program to give veterans with advanced cancer access to its genomic profiling tests, according to AJMC.
Under the agreement, all of Foundation Medicine's tests, including one for solid tumors and one for hematological malignancies, will be available to veterans. Results from these tests can be used to inform more personalized treatments.
Cindy Perettie, CEO at Foundation Medicine, said in a news release: "Our tests are critical to determining the genomic drivers of cancer and what makes each patient's disease unique, to enable a personalized treatment approach. It is imperative that every advanced cancer patient has access to this information, and we are privileged to provide our tests to the people who served our country."